Age-related macular degeneration: A socioeconomic time bomb in our aging society;Altersbedingte makuladegeneration: Sozioökonomische zeitbombe in der alternden gesellschaft

Ophthalmologe

Volumn 103, Issue 9, 2006, Pages 742-748

  Schrader, W F ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Age related macular degeneration; Bevacizumab; Pegaptanib; Photodynamic therapy; Ranibizumab

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB;

AGING; ARTICLE; COST; COST OF ILLNESS; DEMOGRAPHY; EUROPE; GERMANY; HUMAN; INCIDENCE; PHOTODYNAMIC THERAPY; PREVALENCE; RETINA MACULA AGE RELATED DEGENERATION; SOCIOECONOMICS; VISUAL IMPAIRMENT;

AGE FACTORS; AGED; AGED, 80 AND OVER; COST OF ILLNESS; EUROPE; GERMANY; HEALTH CARE COSTS; HUMANS; INCIDENCE; MACULAR DEGENERATION; SOCIOECONOMIC FACTORS;

EID: 33748791240     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-006-1418-4     Document Type: Article

References (27)

1. Arias E (2004) United States Life Tables, 2002. National Vital Statistics Report 53: 1-39
2. Augood CA, de Jong PT, Chakravarthy U et al. (2006) Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). Arch Ophthalmol 124: 529-535
3. Bartz-Schmidt KU, Holz F (2006) Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, des Berufsverbands der Augenärzte Deutschlands und der Retinologischen Gesellschaft zu aktuellen therapeutischen Möglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration. Ophthalmologe 103: 447
4. Bertram B (2005) Blindheit und Sehbehinderung in Deitschland: Ursachen und Häufigkeit. Augenarzt 39: 267-268
5. Bressler NM, Bressler SB, West SK et al. (1989) The grading and prevalence of macular degeneration in Chesapeake Bay watermen. Arch Ophthalmol 107: 847-852
6. Bressler NM and Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 119: 198-207
7. Brown GC, Brown M, Campanella J et al. (2005) The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration-a value based reappraisal with 5-year-data. Am J Ophthalmol 140: 679-687
8. Chia EM, Wang JJ, Rochtchina E et al. (2004) Impact of bilateral visual impairment on health-related quality of life: the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci 45: 71-76
9. Mitteilung des Deutscher Blinden- und Sehbehindertenverband e.V., 2006
10. Ziemssen F, Salvatore Grisanti S, Bartz-Schmidt KU, Schulz M (2006) Innovative Therapien für eine häufige Erblindungsursache. Pharmazeutische Zeitung 23: 1395
11. Friedman DS, Munoz B, Tomany SC et al. (2004) Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004 Apr;122: 564-572
12. Grein HJ (2003) Low-Vision - Versorgung Sehbehinderter mit vergrößernden Sehhilfen. Ophthalmologe 99: 794-806
13. Heier JS, Shapiro H, Singh AA (2006) Randomized, Controlled Phase III Study of Ranibizumab (Lucentis ®) for Minimally Classic or Occult Neovascular Age-Related Macular Degeneration: Two-Year Efficacy Results of the MARINA Study. Invest Ophthalmol Vis SCi 47: ARVO E-Abstract 2959
14. Klein R, Klein BEK, Linton KLP (1992) Prevalence of age related maculopathy. The Beaver Dam Eye Study. Ophthalmology 99: 933-943
15. Knudtson MD, Klein BE, Klein R (2006) Age-related eye disease, visual impairment, and survival: the Beaver Dam Eye Study. Arch Ophthalmol 124: 243-249
16. Korotkin A, Kozak I, Morrison VL et al. (2006) An Emerging Problem: Recurrence of CNV in AMD is Common After Cessation of 24 Month Treatment With Ranibizumab (Lucentis®). Invest Ophthalmol Vis Sci 47: ARVO E-Abstract 2961
17. Krumpaszky HG, Haas A, Klauss V et al. (1997) Neuerblindungen in Württemberg-Hohenzollern. Ophthalmologe 94: 234-236
18. Leibowitz H, Krueger DE, Maunder LR et al. (1980) The Framingham Eye Study Monograph. An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults. Surv Ophthalmol 24: 335-610
19. Miller JW, Shapiro H, Acharya N et al. (2006) Randomized, Controlled Phase III Study of Ranibizumab (Lucentis®) for Minimally Classic or Occult Neovascular Age-Related Macular Degeneration: Two-Year Safety Results of the MARINA Study. Invest Ophthalmol Vis Sci 47: ARVO E-Abstract 3539
20. Pauleikhoff D, Bornfeld N, Gabel VP et al. (2005) Konsenspapier der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbandes der Augenärzte - Stellungnahme zur aktuellen Therapie der neovaskulären AMD. Klin Monatsbl Augenheilkd 222: 381-388
21. Pötzsch O, Sommer B, StatistischesBundesamt (2003) Bevölkerung Deutschlands bis 2050 - Ergebnisse der 10. koordinierten Bevö lkerungsvorausberechnung. Statistisches Bundesamt, Wiesbaden
22. Rosenfeld PJ, Fung AE, Lalwan GA (2006) Visual Acuity Outcomes Following a Variable-Dosing Regimen for Ranibizumab (Lucentis®) in Neovascular AMD: The PrONTO Study. Invest Ophthalmol Vis Sci 47: ARVO E-Abstract 2958
23. Schmidt-Erfurth UM, Gabel P, Hohman T (2006) Preliminary Results From an Open-Label, Multicenter, Phase II Study Assessing the Effects of Same-Day Andministration of Ranibizumab (Lucentis®) and Verteporfin PDT (PROTECT Study). Invest Ophthalmol Vis Sci 47: ARVO E-Abstract 2960
24. Schrader WF, Beisel S, Keilhauer CN (2006) Three Years Results of Photodynamic Therapy in Age Related Macular Degeneration. Invest. Ophthalmol. Vis Sci 47: ARVO E-Abstract 351
25. Statistisches Bundesamt (1997) Schwerbehinderte. Gesundheitswesen Fachserie 13, Reihe 5.1.
26. Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with Verteporfin. One-year results of 2 randomized clinical trials - TAP Report 1. Arch Ophthalmol 1999; 117: 1329-1345
27. Vingerling JR, Dielemans I, Hofman A et al. (1995) The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 102: 205-210